newsfilter
← Latest News
GlobeNewswire·

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027 Showcased the